Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2021 Oct 1;34(9):743–749. doi: 10.3967/bes2021.103

Seroprevalence of IgM and IgG Antibodies against SARS-CoV-2 in Asymptomatic People in Wuhan: Data from a General Hospital Near South China Seafood Wholesale Market during March to April in 2020

Rui Jie LING a,&, Yi Han YU a,&, Jia Yu HE b, Ji Xian ZHANG a, Sha XU a, Ren Rong SUN a, Wang Cai ZHU a, Ming Feng CHEN b, Tao LI b,###, Hong Long JI c,##, Huan Qiang WANG b,#
PMCID: PMC8485512  PMID: 34530966

The content is available as a PDF (1.7 MB).

Biographies

Biographical notes of the first authors: LING Rui Jie, male, born in 1966, Chief Physician, majoring in occupational diseases prevention

YU Yi Han, male, born in 1976, Associate Chief Physician, majoring in respiratory diseases treatment.

Footnotes

This work was supported by Advisory Research Project of the Chinese Academy of Engineering in 2019 [2019-XZ-70].

REFERENCES

  • 1.Bustin SA, Nolan T. RT-qPCR testing of SARS-CoV-2: a primer. Int J Mol Sci. 2020;21:3004. doi: 10.3390/ijms21083004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Zhao JJ, Yuan Q, Wang HY. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71:2027–2034. doi: 10.1093/cid/ciaa344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Pollán M, Pérez-Gómez B, Pastor-Barriuso R. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535–544. doi: 10.1016/S0140-6736(20)31483-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Garcia-Basteiro AL, Moncunill G, Tortajada M. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500. doi: 10.1038/s41467-020-17318-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Zhang WJ, Lv X, Huang C. Clinical evaluation and application of detection of IgM and IgG antibodies against SARS-CoV-2 using a colloidal gold immunochromatography assay. Chin J Virol. 2020;36:348–354. (In Chinese) [Google Scholar]
  • 7.Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107:71–76. doi: 10.1093/oxfordjournals.aje.a112510. [DOI] [PubMed] [Google Scholar]
  • 8.Stringhini S, Wisniak A, Piumatti G. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:313–319. doi: 10.1016/S0140-6736(20)31304-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zeng FF, Dai C, Cai PC. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020;92:2050–2054. doi: 10.1002/jmv.25989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bao CP, Liu XH, Zhang H. Coronavirus disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis. J Am Coll Radiol. 2020;17:701–709. doi: 10.1016/j.jacr.2020.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

Supplementary Data

Supporting materials
mmc1.pdf (1.1MB, pdf)

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting materials
mmc1.pdf (1.1MB, pdf)

Articles from Biomedical and Environmental Sciences are provided here courtesy of Elsevier

RESOURCES